Cogent Biosciences (COGT) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.59

Estimate

-$0.55

Surprise

-7.2%

Score today

5.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Cogent Biosciences (COGT) reported a wider loss than forecast — adjusted EPS of -$0.59 against the -$0.55 estimate (a 7.2% shortfall).

• Cogent Biosciences Reports Third Quarter 2026 Financial Results and Business Highlights — fiscal.ai, 2026-11-05
• Cogent Biosciences Q3 GAAP EPS $(0.59) vs $(0.50) YoY — benzinga, 2026-11-05
• Cogent Biosciences Says Bezuclastinib GIST PDUFA Date 30 Nov, NonAdvSM 30 Dec, AdvSM 29 Jun 2027; Cash $791.1M Funds Ope — benzinga, 2026-11-05

TrendMatrix currently rates COGT Sell at 5.2/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -7.2% surprise compares with a -2.0% four-quarter average. Next scheduled report: 2027-02-16.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$31.64

Price target

$48.56

Stop

$29.43

Upside to target

+53.5%

Reward-to-risk

4.3:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$5.49B

P/E (fwd)

-26.4

52-week range

$13.93–$43.73

Off 52-week high

27.6%

RSI (14)

57

Volume vs avg

0.69×

Score today

5.2/10